180 results on '"Cuccarini, Valeria"'
Search Results
2. Temporal lobe epilepsy with isolated amygdala enlargement: anatomo-electro-clinical features and long-term outcome
3. Distinctive electro-clinical, neuroimaging and histopathological features of temporal encephaloceles associated to epilepsy
4. In vivo brain MR spectroscopy in gliomas: clinical and pre-clinical chances
5. High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient
6. Gliomatosis cerebri (GC) or GC-like? A picture to be reconsidered in neuro-oncology based on large retrospective analysis of GC series
7. In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting
8. Development of A Radiomic Model for MGMT Promoter Methylation Detection in Glioblastoma Using Conventional MRI
9. CTIM-26. IMPACT ON SURVIVAL OF INTERFERON-ALPHA DELIVERY IN GLIOBLASTOMA WITH UNMETHYLATED MGMT BY IMMUNO-GENE THERAPY WITH TEMFERON
10. 639 Intra-tumor delivery of IFN-alpha by Tie-2 transduced monocytes associated with favorable 2-year survival in unmethylated MGMT GBM patients: preliminary results of TEM-GBM phase 1/2a study
11. Response assessment of GBM during immunotherapy by delayed contrast treatment response assessment maps.
12. In-vivo brain H1-MR-Spectroscopy identification and quantification of 2-hydroxyglutarate in L-2-Hydroxyglutaric aciduria
13. Development of A Radiomic Model for MGMT Promoter Methylation Detection in Glioblastoma Using Conventional MRI.
14. Case report: Multiple brain intravascular papillary endothelial hyperplasia: incidence, diagnostic challenges, and management approach
15. Reprogramming Macrophages Using Autologous Hematopoietic Stem Cells As Immunotherapy for Glioblastoma: TEM-GBM Study (NCT03866109)
16. 648 Autologous macrophage-based immunotherapy Induces a pro-inflammatory state in GBM tumor microenvironment – (TEM-GBM)
17. Morphometry and network-based atrophy patterns in SCN1A-related Dravet syndrome.
18. A Critical Appraisal of the Quality of Vertigo Practice Guidelines Using the AGREE II Tool: A EuroAIM Initiative
19. CLRM-08 TARGETING IMMUNE-PAYLOAD TO THE GLIOBLASTOMA TUMOR MICROENVIRONMENT USING A MACROPHAGE-BASED TREATMENT RELYING ON AUTOLOGOUS, GENETICALLY MODIFIED, HEMATOPOIETIC STEM CELL-BASED THERAPY: THE TEM-GBM STUDY (NCT03866109)
20. Advanced MRI may complement histological diagnosis of lower grade gliomas and help in predicting survival
21. Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis
22. Abstract 5213: Genetically modified Tie-2 expressing monocytes target IFN-α2 to the glioblastoma tumor microenvironment (TME): Preliminary data from the TEM-GBM Phase 1/2a study
23. Harnessing genetically engineered hematopoietic progenitor cells to redirect the tumor immune microenvironment against glioblastoma (TEM-GBM Study).
24. TEM-GBM: An Open-Label, Phase I/IIa Dose-Escalation Study Evaluating the Safety and Efficacy of Genetically Modified Tie-2 Expressing Monocytes to Deliver IFN-α within Glioblastoma Tumor Microenvironment
25. CTIM-19. TEM-GBM: A PHASE I-IIA DOSE-ESCALATION STUDY DELIVERING IFN-Α WITHIN GLIOBLASTOMA MULTIFORME TUMOR MICROENVIRONMENT BY GENETICALLY MODIFIED TIE-2 EXPRESSING MONOCYTES
26. Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma
27. IMMU-01. TEM-GBM: AN OPEN-LABEL, PHASE I/IIA DOSE-ESCALATION STUDY EVALUATING THE SAFETY AND EFFICACY OF GENETICALLY MODIFIED TIE-2 EXPRESSING MONOCYTES TO DELIVER IFN-A WITHIN GLIOBLASTOMA TUMOR MICROENVIRONMENT
28. FABP4 is a candidate marker of cerebellar liponeurocytomas
29. Genetic Engineering of Hematopoietic Progenitor Stem Cells for Targeted IFN-α Immunotherapy Reprogramming the Solid Tumor Microenvironment: A First-in-Man Study in Glioblastoma Multiforme (NCT03866109)
30. sj-pdf-1-tmj-10.1177_03008916211052330 ��� Supplemental material for Carcinomatosis under control by osimertinib in EGFR and TP53 mutated lung adenocarcinoma
31. Abstract CT180: Changes in immunologic responses and in the tumor microenvironment in patients with glioblastoma multiforme treated with IFN-a immune cell and gene therapy (TEM-GBM_001 Study)
32. Integrated use of tumor AI volumetrics and advanced MRI to assess early response to Temferon in a phase 2 GBM trial: A novel paradigm.
33. Long-term vocal functional results after glottectomy: a multi-dimensional analysis
34. Central Nervous System Non-Von Hippel-Lindau (VHL) Hemangioblastoma Evolving to Dissemination: Is Anti-Angiogenic Therapy an Option?
35. High tumor mutational burden and T-cell activation are associated with long-term response to anti-PD1 therapy in Lynch syndrome recurrent glioblastoma patient
36. CTIM-24. AUTOLOGOUS CD34+ ENRICHED HEMATOPOIETIC PROGENITOR CELLS GENETICALLY MODIFIED FOR HUMAN INTERFERON-α2, ARE WELL TOLERATED & RAPIDLY ENGRAFT IN PATIENTS WITH GLIOBLASTOMA MULTIFORME (TEM-GBM_001 STUDY)
37. Brain Regions Involved in Conceptual Retrieval in Sighted and Blind People
38. Surgery and topic cidofovir for nasal squamous papillomatosis in HIV+ patient
39. Methylenetetrahydrofolate reductase gene mutations as risk factors for sudden hearing loss
40. Erratum to: Radiosurgery reirradiation for high-grade glioma recurrence: a retrospective analysis
41. In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting
42. A novel lecithin-based delivery form of Boswellic acids as complementary treatment of radiochemotherapy-induced cerebral edema in patients with glioblastoma multiforme: a longitudinal pilot experience
43. Expansion of effector and memory T cells is associated with increased survival in recurrent glioblastomas treated with dendritic cell immunotherapy
44. Carcinomatosis under control by osimertinib in EGFRand TP53mutated lung adenocarcinoma
45. Different neural networks for conceptual retrieval in sighted and blind
46. Brain Gliomas: Multicenter Standardized Assessment of Dynamic Contrast-enhanced and Dynamic Susceptibility Contrast MR Images
47. Tetanus toxoid pre-conditioning in recurrent glioblastoma treated with dendritic cell immunotherapy is associated to CD8+ T cell response.
48. Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+T cell activation in the presence of adjuvant temozolomide
49. MRI in Glioma Immunotherapy: Evidence, Pitfalls, and Perspectives
50. Survival gain in glioblastoma patients treated with dendritic cell immunotherapy is associated with increased NK but not CD8+ T cell activation in the presence of adjuvant temozolomide
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.